ANI Pharmaceuticals Completes Buyout of Royalty Obligation for Iluvien, Yutiq

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

ANI Pharmaceuticals Completes Buyout of Royalty Obligation for Iluvien, Yutiq

, MT Newswires - 8:19 AM ET 3/18/2025 mergers-and-acquisitions

08:19 AM EDT, 03/18/2025 (MT Newswires) -- ANI Pharmaceuticals ( ANIP ) said Tuesday that it has completed the buyout of its 3.125% perpetual royalty obligation to SWK Funding on global net revenue of Iluvien and Yutiq for a one-time payment of $17.3 million.

The company said it financed the buyout with cash on hand, and that no additional royalty is due to SWK on net revenue beginning Jan. 1 of this year and forward.

Shares of the company were down more than 1% in recent Tuesday premarket activity.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.